Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Declines By 59.4%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) saw a significant decline in short interest in March. As of March 31st, there was short interest totalling 342,200 shares, a decline of 59.4% from the March 15th total of 843,600 shares. Based on an average daily volume of 841,800 shares, the days-to-cover ratio is currently 0.4 days. Currently, 14.0% of the shares of the stock are sold short.

CERo Therapeutics Stock Performance

Shares of CERO stock opened at $0.67 on Tuesday. The stock’s fifty day moving average is $1.26 and its 200-day moving average is $6.45. CERo Therapeutics has a 52 week low of $0.64 and a 52 week high of $184.99.

Institutional Investors Weigh In On CERo Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. ARCH Venture Management LLC raised its stake in shares of CERo Therapeutics by 550.4% in the fourth quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock worth $564,000 after acquiring an additional 7,949,265 shares during the last quarter. Avantax Planning Partners Inc. increased its holdings in shares of CERo Therapeutics by 89.9% in the fourth quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock valued at $155,000 after purchasing an additional 1,224,021 shares in the last quarter. Finally, Parallel Advisors LLC bought a new position in CERo Therapeutics in the 1st quarter worth approximately $161,000. Institutional investors own 29.64% of the company’s stock.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.